Janus Henderson Global Life Sciences T (JAGLX)

Fund Assets	4.49B
Expense Ratio	0.92%
Min. Investment	$2,500
Turnover	35.00%
Dividend (ttm)	3.87
Dividend Yield	5.01%
Dividend Growth	33.40%
Payout Frequency	Annual
Ex-Dividend Date	Dec 6, 2024

Previous Close	77.21
YTD Return	15.68%
1-Year Return	8.31%
5-Year Return	50.74%
52-Week Low	61.32
52-Week High	79.14
Beta (5Y)	0.61
Holdings	103
Inception Date	Dec 31, 1998

About JAGLX

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

• Fund Family: Janus Henderson
• Category: Health
• Stock Exchange: NASDAQ
• Ticker Symbol: JAGLX
• Share Class: Class T
• Index: MSCI World/Health Care NR

Performance

JAGLX had a total return of 8.31% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.35%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JFNIX	Class I	0.77%
JNGLX	Class D	0.80%
JFNAX	Class A	0.98%

Top 10 Holdings

39.38% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	8.39%
AstraZeneca PLC	AZN	4.55%
Johnson & Johnson	JNJ	4.54%
UnitedHealth Group Incorporated	UNH	3.91%
Abbott Laboratories	ABT	3.23%
Boston Scientific Corporation	BSX	3.08%
argenx SE	ARGX	3.05%
AbbVie Inc.	ABBV	3.04%
Sanofi	SAN	2.97%
Novartis AG ADR	NVSN.MX	2.62%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 6, 2024	$3.86839	Dec 6, 2024
Dec 7, 2023	$2.89991	Dec 7, 2023
Dec 20, 2022	$0.09366	Dec 20, 2022
Dec 20, 2021	$6.73381	Dec 20, 2021
Dec 17, 2020	$5.50316	Dec 17, 2020
Dec 17, 2019	$3.76557	Dec 17, 2019